NCT07244003

Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

Efficacy and Safety of the Triple Combination Therapy of Met/SGLT-2i/GLP-1RA or Other Oral Antidiabetic Drugs in Patients With Type 2 Diabetes Exhibiting Poor Glycemic Control

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 430 (estimated)
• Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The main objective of this study is to compare the efficacy and safety of the triple combination therapy of Met/SGLT-2i/GLP-1RA or other oral antidiabetic drugs in patients with type 2 diabetes exhibiting poor glycemic control.

Conditions

• T2DM (Type 2 Diabetes Mellitus)

Interventions

Type	Name	Description
DRUG	Metformin	The dosage of metformin hydrochloride was consistent with baseline.
DRUG	Triple Therapy of Other Oral Antidiabetic Drugs	The dosage of metformin hydrochloride was consistent with baseline. The usage and dosage of other hypoglycemic drugs were referred to their respective instructions.
DRUG	ganagliflozin	Ganagliflozin tablet : 50mg/d.
DRUG	liraglutide	Liraglutide injection: 0.6 mg/d for the first week, 1.2 mg/d for the second week, and 1.8 mg/d after the third week.

Timeline

• Start date: 2025-03-29
• Primary completion: 2027-12-31
• Completion: 2028-06-30
• First posted: 2025-11-24
• Last updated: 2025-11-24

Locations

1 site across 1 country: China